Expression of Sialyl Lewis X, Sialyl Lewis a, E-cadherin and Cathepsin-D in human breast cancer: Immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1615-1622

  Jeschke, Udo ^a   Mylonas, Ioannis ^a   Shabani, Naim ^a   Kunert Keil, Christiane ^b   Schindlbeck, Christian ^a   Gerber, Bernd ^a   Friese, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Breast cancer; Cathepsin D; E cadherin; Sialyl Lewis a; Sialyl Lewis X

Indexed keywords

CATHEPSIN D; SIALYL LEWIS A ANTIGEN; SIALYL LEWIS X ANTIGEN; UNCLASSIFIED DRUG; UVOMORULIN;

ANTIGEN EXPRESSION; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER PATIENT; CARBOHYDRATE ANALYSIS; CARCINOMA IN SITU; CELL PROLIFERATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENDOTHELIUM CELL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE;

BREAST NEOPLASMS; CADHERINS; CARCINOMA IN SITU; CATHEPSIN D; GANGLIOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; OLIGOSACCHARIDES;

EID: 21244447444     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Magdolen V, Kruger A, Sato S, Nagel J, Sperl S, Reuning U, Rettenberger P, Magdolen U and Schmitt M: Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo. Rec Results Cancer Res 162: 43-63, 2003.
2. Wingo PA, Ries LA and Giovino GA: Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91: 675-690, 1999.
3. Fisher B and Slack NH: Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 131: 79-88, 1970.
4. Fisher B, Slack N and Katrych D: Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528-534, 1975.
5. Valagussa P, Bonadonna G and Veronesi U: Patterns of relapse and survival in operable breast carcinoma with positive and negative axillary nodes. Tumori 64: 241-258, 1978.
6. Henderson IC and Canellos GP: Cancer of the breast: the past decade (second of two parts). N Engl J Med 302: 78-90, 1980.
7. Carter CL, Allen C and Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181-187, 1989.
8. Adair F, Berg J, Joubert L et al: Long-term followup of breast cancer patients: The 30-year report. Cancer 33: 1145-1150, 1974.
9. EBCTCG: Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352: 930-942, 1998.
10. EBCTCG: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351: 1451-1467, 1998.
11. Gerber B: Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003. Zentralbl Gynakol 125: 315-321, 2003.
12. Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G and Friese K: Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19: 960-971, 2001.
13. Liotta LA, Stetler-Stevenson WG and Steeg PS: Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest 9: 543-51, 1991.
14. Alpaugh ML, Tomlinson JS, Kasraeian S and Barsky SH: Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21: 3631-3643, 2002.
15. Ohyama C, Kanto S, Kato K, Nakano O, Arai Y, Kato T, Chen S, Fukuda MN and Fukuda M: Natural killer cells attack tumor cells expressing high levels of sialyl Lewis x oligosaccharides. Proc Natl Acad Sci USA 99: 13789-13794, 2002.
16. Trinchieri G: Biology of natural killer cells. Adv Immunol 47: 187-376, 1989.
17. Cleton-Jansen AM: E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 4: 5-8, 2002.
18. Berx G and Van Roy F: The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293, 2001.
19. Alpaugh ML, Tomlinson JS, Ye Y and Barsky SH: Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 161: 619-628, 2002.
20. Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM and Roger P: Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 297: 157-70, 2000.
21. Spyratos F, Brouillet JP, Defrenne A, Hacene J, Rouesse T, Maudelonde M, Brunei C, Andrieu A, Desplaces A and Rochefort H: Cathepsin-D: an independant prognostic factor for metastasis of breast cancer. Lancet 5672: 1115-1118, 1989.
22. Mylonas I, Makovitzky J, Richter DU, Jeschke U, Briese V and Friese K: Cathepsin D expression in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Acta Histochem 105: 245-252, 2003.
23. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Hofler H, Janicke F and Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997.